@article{3123584,
    title = "Anti-vascular endothelial growth factor for unilateral acute idiopathic maculopathy",
    author = "Mylonas, G. and Prager, F. and Wetzel, B. and Malamos, P. and Deak, G. and Amon, M.",
    journal = "European Journal of Ophthalmology",
    year = "2018",
    volume = "28",
    number = "2",
    pages = "256-258",
    publisher = "SAGE Publications Ltd",
    issn = "1120-6721, 1724-6016",
    doi = "10.5301/ejo.5001070",
    keywords = "aflibercept;  vasculotropin;  aflibercept;  angiogenesis inhibitor;  fusion protein;  vasculotropin A;  vasculotropin receptor;  VEGFA protein, human, adult;  Article;  case report;  central scotoma;  clinical article;  female;  fluorescence angiography;  human;  intraocular pressure;  laryngitis;  ophthalmoscopy;  priority journal;  retina maculopathy;  retinal thickness;  retrospective study;  slit lamp microscopy;  spectral domain optical coherence tomography;  unilateral acute idiopathic maculopathy;  unilateral acute idiopathic maculopathy;  visual acuity;  visual impairment;  acute disease;  antagonists and inhibitors;  intravitreal drug administration;  retina disease;  scotoma, Acute Disease;  Adult;  Angiogenesis Inhibitors;  Female;  Humans;  Intravitreal Injections;  Receptors, Vascular Endothelial Growth Factor;  Recombinant Fusion Proteins;  Retinal Diseases;  Retrospective Studies;  Scotoma;  Vascular Endothelial Growth Factor A;  Visual Acuity",
    abstract = "Purpose: To describe a case of unilateral acute idiopathic maculopathy (UAIM) response to intravitreal therapy with aflibercept (Eylea). Methods: Retrospective case report. Results: A 36-year-old woman with sudden visual impairment and central scotoma was found to have a UAIM in her left eye. Three weeks after continuous worsening of her visual acuity and central scotoma, the patient was treated with intravitreal injections of aflibercept. The visual acuity increased and the macula lesion regressed, causing macula scarring after 2 injections. Conclusions: Intravitreal injections of aflibercept could be a therapy option in patients with UAIM without signs of spontaneous resolution of the clinical manifestations and visual improvement. © The Author(s) 2017."
}